Ionis Pharmaceuticals Inc... (IONS)
Ionis Pharmaceuticals Statistics
Share Statistics
Ionis Pharmaceuticals has 158.97M shares outstanding. The number of shares has increased by 8.91% in one year.
Shares Outstanding | 158.97M |
Shares Change (YoY) | 8.91% |
Shares Change (QoQ) | 0.68% |
Owned by Institutions (%) | 99.99% |
Shares Floating | 154.59M |
Failed to Deliver (FTD) Shares | 5.01K |
FTD / Avg. Volume | 0.3% |
Short Selling Information
The latest short interest is 10.24M, so 6.49% of the outstanding shares have been sold short.
Short Interest | 10.24M |
Short % of Shares Out | 6.49% |
Short % of Float | 7.04% |
Short Ratio (days to cover) | 6.49 |
Valuation Ratios
The PE ratio is -11.52 and the forward PE ratio is -12.36. Ionis Pharmaceuticals's PEG ratio is -0.61.
PE Ratio | -11.52 |
Forward PE | -12.36 |
PS Ratio | 7.41 |
Forward PS | 1.9 |
PB Ratio | 8.88 |
P/FCF Ratio | -9.57 |
PEG Ratio | -0.61 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Ionis Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.47, with a Debt / Equity ratio of 2.39.
Current Ratio | 8.47 |
Quick Ratio | 8.43 |
Debt / Equity | 2.39 |
Debt / EBITDA | -2.96 |
Debt / FCF | -2.58 |
Interest Coverage | -5.63 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $659.62K |
Profits Per Employee | $-424.6K |
Employee Count | 1,069 |
Asset Turnover | 0.23 |
Inventory Turnover | 0.9 |
Taxes
Income Tax | -6.17M |
Effective Tax Rate | 1.34% |
Stock Price Statistics
The stock price has increased by -33.46% in the last 52 weeks. The beta is 0.28, so Ionis Pharmaceuticals's price volatility has been higher than the market average.
Beta | 0.28 |
52-Week Price Change | -33.46% |
50-Day Moving Average | 32.27 |
200-Day Moving Average | 39.09 |
Relative Strength Index (RSI) | 35.74 |
Average Volume (20 Days) | 1.67M |
Income Statement
In the last 12 months, Ionis Pharmaceuticals had revenue of 705.14M and earned -453.9M in profits. Earnings per share was -3.04.
Revenue | 705.14M |
Gross Profit | 693.92M |
Operating Income | -475.08M |
Net Income | -453.9M |
EBITDA | -475.08M |
EBIT | -477.06M |
Earnings Per Share (EPS) | -3.04 |
Balance Sheet
The company has 242.08M in cash and 1.41B in debt, giving a net cash position of -1.17B.
Cash & Cash Equivalents | 242.08M |
Total Debt | 1.41B |
Net Cash | -1.17B |
Retained Earnings | -2.25B |
Total Assets | 3B |
Working Capital | 2.31B |
Cash Flow
In the last 12 months, operating cash flow was -500.95M and capital expenditures -45.28M, giving a free cash flow of -546.23M.
Operating Cash Flow | -500.95M |
Capital Expenditures | -45.28M |
Free Cash Flow | -546.23M |
FCF Per Share | -3.65 |
Margins
Gross margin is 98.41%, with operating and profit margins of -67.37% and -64.37%.
Gross Margin | 98.41% |
Operating Margin | -67.37% |
Pretax Margin | -65.25% |
Profit Margin | -64.37% |
EBITDA Margin | -67.37% |
EBIT Margin | -67.37% |
FCF Margin | -77.46% |
Dividends & Yields
IONS does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for IONS is $61, which is 114% higher than the current price. The consensus rating is "Buy".
Price Target | $61 |
Price Target Difference | 114% |
Analyst Consensus | Buy |
Analyst Count | 19 |
Scores
Altman Z-Score | 0.75 |
Piotroski F-Score | 2 |